Baylor College of Medicine: MAPK4, Novel Therapeutic Target for Triple-Negative Breast Cancer
January 12, 2022
January 12, 2022
HOUSTON, Texas, Jan. 12 (TNSJou) -- The Baylor College of Medicine issued the following news:
Scientific evidence supporting the involvement of the enzyme MAPK4 in cancer growth and resistance to certain therapies has been growing quickly. In a current study published in the journal Nature Communications, a team at Baylor College of Medicine and collaborating institutions reports that MAPK4 seems to play an important role in triple-negative breast cancer (TNBC), a devastating diseas . . .
Scientific evidence supporting the involvement of the enzyme MAPK4 in cancer growth and resistance to certain therapies has been growing quickly. In a current study published in the journal Nature Communications, a team at Baylor College of Medicine and collaborating institutions reports that MAPK4 seems to play an important role in triple-negative breast cancer (TNBC), a devastating diseas . . .